Samsung Bioepis has unveiled Phase III interim analysis data for SB15, a proposed biosimilar for Eylea (aflibercept), in a paper presented before the American Academy of Ophthalmology (AAO) 2022 Annual Meeting held between 30 September and 3 October.
Samsung Bioepis also took the opportunity to present two post-hoc analyses of post-Phase III, one-year results for Byooivz (ranibizumab), also...



